These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10584563)

  • 1. [Secondary leukemias: their clinical features, incidence among populations at risk, mechanisms and new strategy for prediction].
    Abe T
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):1999-2008. PubMed ID: 10584563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromatin structural elements and chromosomal translocations in leukemia.
    Zhang Y; Rowley JD
    DNA Repair (Amst); 2006 Sep; 5(9-10):1282-97. PubMed ID: 16893685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Leukemias induced by anticancer chemotherapies].
    Harousseau JL
    Bull Cancer; 1999 Nov; 86(11):929-38. PubMed ID: 10586109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do children have increased susceptibility for developing secondary acute myelogenous leukemia?
    Pyatt DW; Hays SM; Cushing CA
    Chem Biol Interact; 2005 May; 153-154():223-9. PubMed ID: 15878160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Second cancers associated with the cancer treatment and their possible control].
    Abe T; Nomura K
    Nihon Rinsho; 2003 Jun; 61(6):1045-51. PubMed ID: 12806958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.
    Karp JE; Smith MA
    Semin Oncol; 1997 Feb; 24(1):103-13. PubMed ID: 9045296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-related leukaemia--a clinical and scientific challenge.
    Ng A; Taylor GM; Eden OB
    Cancer Treat Rev; 2000 Oct; 26(5):377-91. PubMed ID: 11006138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced endoreduplication in CHO cells: DNA damage and inhibition of topoisomerase II.
    Cantero G; Pastor N; Mateos S; Campanella C; Cortés F
    Mutat Res; 2006 Jul; 599(1-2):160-6. PubMed ID: 16574165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-related leukemia associated with alkylating agents.
    Davies SM
    Med Pediatr Oncol; 2001 May; 36(5):536-40. PubMed ID: 11340608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary myelodysplastic syndromes and acute leukemias.
    Zeidman A; Dayan DB; Mittelman M
    Haematologia (Budap); 1995; 27(1):23-8. PubMed ID: 12051292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia.
    Worrillow LJ; Allan JM
    Oncogene; 2006 Mar; 25(12):1709-20. PubMed ID: 16278672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.
    Takeyama K; Seto M; Uike N; Hamajima N; Ino T; Mikuni C; Kobayashi T; Maruta A; Muto Y; Maseki N; Sakamaki H; Saitoh H; Shimoyama M; Ueda R
    Int J Hematol; 2000 Feb; 71(2):144-52. PubMed ID: 10745624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
    Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
    Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.
    Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C
    Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG; Malmgren JA; Atwood M
    Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.